Venous thromboembolism syndrome in gynecological cancer

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 458-471

  Wang, X ^a,b   Fu, S ^a   Freedman, R S ^b   Kavanagh, J J ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antiangiogenic; Gynecology; VEGF; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANASTROZOLE; ANTHRACYCLINE; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIVITAMIN K; BEVACIZUMAB; CISPLATIN; COUMARIN; CYCLOPHOSPHAMIDE; DALTEPARIN; DOCETAXEL; ENOXAPARIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GEMCITABINE; GOSERELIN; HEPARIN; HORMONE; LEUPRORELIN; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; SEMAXANIB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VINCRISTINE; WARFARIN;

ANEMIA; ASTHENIA; BLEEDING; BLOOD CLOTTING; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GYNECOLOGIC CANCER; HORMONAL THERAPY; HUMAN; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; THROMBOSIS; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ASPIRIN; BLOOD COAGULATION; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ERYTHROPOIETIN; FEMALE; GENITAL NEOPLASMS, FEMALE; HEPARIN; HUMANS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOSIS; VITAMIN K;

EID: 33645372796     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00515.x     Document Type: Review

References (141)

1. Trousseau A. Phlegmasia alba dolens: clinique medicale de l'Hotel-Dieu de Paris 2nd edn. Paris, France J.B.Balliere et Fils 1865 654 712.
2. Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med 1981 24 23 35.
3. Monreal M Fernandez-Llamazares J Perandreu J et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997 78 1316 8.
4. Rance A Emmerich J Guedj C et al. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 1997 350 1448 9.
5. Hettiarachchi RJ Lok J Prins MH et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998 83 180 5.
6. Rajan R Levine M Gent M et al. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 1998 79 19 22.
7. Achkar A Laaban JP Horellou MH et al. Prospective screening for occult cancer in patients with venous thromboembolism [abstract]. Thromb Haemost 1997 78 Suppl 383.
8. Prandoni P Lensing AW Buller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992 327 1128 33.
9. Sorensen HT Mellemkjaer L Steffensen FH et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998 338 1169 73.
10. Baron JA Gridley G Weiderpass E et al. Venous thromboembolism and cancer. Lancet 1998 351 1077 80.
11. Piccioli A Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol 2001 106 13 7.
12. Blom JW Doggen CJ Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005 293 715 22.
13. Dainty L Maxwell GL Clarke-Pearson DL et al. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. Gynecol Oncol 2004 93 366 73.
14. Ailawadi M Del Priore G. A comparison of thromboembolic prophylaxis in gynecologic oncology patients. Int J Gynecol Cancer 2001 11 354 8.
15. von Tempelhoff GF Dietrich M Niemann F et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997 77 456 61.
16. Wun T Law L Harvey D et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003 98 1514 20.
17. von Tempelhoff GF Nieman F Heilmann L et al. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin Hemorheol Microcirc 2000 22 107 30.
18. Morgan MA Iyengar TD Napiorkowski BE et al. The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol 2002 84 67 71.
19. Sorensen HT Mellemkjaer L Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000 343 1846 50.
20. Harrington KJ Bateman AR Syrigos KN et al. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol 1997 8 669 73.
21. von Tempelhoff GF Heilmann L Hommel G et al. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer 1998 82 1104 11.
22. Harrison LB Chadha M Hill RJ et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002 7 492 508.
23. Cairns RA Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004 64 2054 61.
24. Yatabe N Kyo S Maida Y et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004 23 3708 15.
25. Crandon AJ Koutts J. Incidence of post-operative deep vein thrombosis in gynaecological oncology. Aust N Z J Obstet Gynaecol 1983 23 216 9.
26. Jeffcoate TN Tindall VR. Venous thrombosis and embolism in obstetrics and gynaecology. Aust N Z J Obstet Gynaecol 1965 5 119 30.
27. Clarke-Pearson DL Jelovsek FR Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 1983 61 87 94.
28. Prandoni P Lensing AW Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996 125 1 7.
29. Clark-Pearson DL DeLong E Synan IS et al. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990 75 684 9.
30. Maxwell GL Synan I Dodge R et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001 98 989 95.
31. Maxwell GL Synan I Hayes RP et al. Preference and compliance in postoperative thromboembolism prophylaxis among gynecologic oncology patients. Obstet Gynecol 2002 100 451 5.
32. Minjarez DA Delorit MA Davidson SA. Spontaneous arterial thrombosis with an advanced ovarian malignancy. Gynecol Oncol 1997 64 176 9.
33. Pathanjali Sharma PV Babu SC Shah PM et al. Arterial thrombosis and embolism in malignancy. J Cardiovasc Surg (Torino) 1985 26 479 83.
34. Fuglsang J Ingerslev J Havsteen H. Recurrent thromboembolism in ovarian cancer. Acta Obstet Gynecol Scand 2004 83 1218 20.
35. Gadducci A Baicchi U Marrai R et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994 53 352 6.
36. Khoo SK Rylatt DB Parsons P et al. Serial D-dimer levels in the assessment of tumor mass and clinical outcome in ovarian cancer. Gynecol Oncol 1988 29 188 98.
37. Rella C Coviello M De Frenza N et al. Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125. Tumori 1993 79 347 51.
38. Wilhelm O Hafter R Henschen A et al. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990 75 1673 8.
39. Kanayma N. The role of D-dimer in diagnosis of ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1991 43 485.
40. Nagy JA Masse EM Herzberg KT et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995 55 360 8.
41. Nagy JA Meyers MS Masse EM et al. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995 55 369 75.
42. Nagy JA Morgan ES Herzberg KT et al. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995 55 376 85.
43. van de Molengraft F Jap P Poels L et al. Tumor cell settling and early invasion of the peritoneum. Clin Exp Metastasis 1989 7 187 99.
44. Wang E Ngalame Y Panelli MC et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005 11 113 22.
45. Semeraro N Montemurro P Conese M et al. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies. Int J Cancer 1990 45 251 4.
46. Carroll NM Elaraj DM Puhlmann M et al. Alterations in tumor necrosis factor-induced endothelial cell procoagulant activity by hyperthermia. Int J Cancer 2004 111 457 62.
47. Clarke-Pearson DL Coleman RE Synan IS et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983 145 606 13.
48. Saphner T Tormey DC Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991 9 286 94.
49. Levine MN Gent M Hirsh J et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988 318 404 7.
50. von Tempelhoff GF Dietrich M Hommel G et al. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996 14 2560 8.
51. Rogers JS II. Murgo AJ Fontana JA et al. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988 6 27 81.
52. Doll DC Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992 19 580 96.
53. Gadducci A Baicchi U Marrai R et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996 60 197 202.
54. Gadducci A Marrai R Baicchi U et al. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer. Anticancer Res 1995 15 2683 6.
55. Mirshahi SS Pujade-Lauraine E Soria C et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment. Cancer 1992 69 2289 92.
56. Salgado R Benoy I Weytjens R et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 2002 87 1437 44.
57. Fujiwara H Kosaka K Hamanishi S et al. Acute elevation of plasma D-dimer levels associated with rupture of an ovarian endometriotic cyst: case report. Hum Reprod 2003 18 338 41.
58. Freedman RS Deavers M Liu J et al. Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2004 2 23.
59. Koh SC Tham KF Razvi K et al. Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost 2001 7 141 8.
60. den Ouden M Ubachs JM Stoot JE et al. Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours. Scand J Clin Lab Invest 1998 58 555 9.
61. Gadducci A Marrai R Baicchi U et al. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol 1997 66 85 8.
62. Rose PG Terrien JM Baker S. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. J Surg Oncol 1994 56 168 71.
63. Clarke-Pearson DL Synan IS Colemen RE et al. The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol 1984 148 1051 4.
64. Myers ER Clarke-Pearson DL Olt GJ et al. Preoperative coagulation testing on a gynecologic oncology service. Obstet Gynecol 1994 83 438 44.
65. Franchi M Ghezzi F Riva C et al. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol 2001 78 232 7 discussion 37-40.
66. Maxwell GL Myers ER Clarke-Pearson DL. Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 2000 95 206 14.
67. Falanga A Ofosu FA Cortelazzo S et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993 85 745 50.
68. Asbury RF Brunetto VL Lee RB et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002 25 557 60.
69. Rose PG Brunetto VL VanLe L et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000 78 212 6.
70. Covens A Thomas G Shaw P et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997 64 126 9.
71. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003 9 425 32.
72. von Tempelhoff GF Heilmann L Pollow K et al. Monitoring of rheologic variables during postoperative high-dose brachytherapy for uterine cancer. Clin Appl Thromb Hemost 2004 10 239 48.
73. Dusenbery KE Carson LF Potish RA. Perioperative morbidity and mortality of gynecologic brachytherapy. Cancer 1991 67 2786 90.
74. Jhingran A Eifel PJ. Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000 46 1177 83.
75. Jacobson GM Kamath RS Smith BJ et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 2005 96 470 4.
76. Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 2002 28 137 40.
77. Fernandez PM Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002 9 401 6.
78. Belting M Dorrell MI Sandgren S et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004 10 502 9.
79. Even-Ram S Uziely B Cohen P et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998 4 909 14.
80. Darmoul D Gratio V Devaud H et al. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003 162 1503 13.
81. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004 50 187 96.
82. Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964 22 832 5.
83. Zacharski LR Henderson WG Rickles FR et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981 245 831 5.
84. Smorenburg SM Vink R Otten HM et al. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001 86 1586 7.
85. Gould MK Dembitzer AD Doyle RL et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999 130 800 9.
86. Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993 23 Suppl. 1 103 6.
87. Lensing AW Prins MH Davidson BL et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995 155 601 7.
88. Prandoni P Lensing AW Buller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992 339 441 5.
89. Green D Hull RD Brant R et al. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992 339 1476.
90. Siragusa S Cosmi B Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996 100 269 77.
91. Hettiarachchi RJ Smorenburg SM Ginsberg J et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999 82 947 52.
92. Cosgrove RH Zacharski LR Racine E et al. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002 28 79 87.
93. Kakkar AK Williamson RC. Antithrombotic therapy in cancer. BMJ 1999 318 1571 2.
94. Zacharski LR Ornstein DL Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000 26 Suppl. 1 69 77.
95. Wojtukiewicz MZ Kozlowski L Ostrowska K et al. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost 2003 89 405 7.
96. Robert F Busby E Marques MB et al. Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 2003 42 237 45.
97. Altinbas M Coskun HS Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004 2 1266 71.
98. Lee AYY Rickles FR Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005 23 2123 9.
99. Klerk CP Smorenburg SM Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005 23 2130 5.
100. Kakkar AK Levine MN Kadziola Z et al. Low Molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004 22 1944 8.
101. Lapierre F Holme K Lam L et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996 6 355 66.
102. Collen A Smorenburg SM Peters E et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000 60 6196 200.
103. Van Noorden C Meade-Tollin L Bosman F. Metastasis. Am Sci 1998 86 130 41.
104. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2004 2 1263 5.
105. Da Silva MS Horton JA Wijelath JM et al. Heparin modulates integrin-mediated cellular adhesion: specificity of interactions with alpha and beta integrin subunits. Cell Commun Adhes 2003 10 59 67.
106. Sandler RS Halabi S Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003 348 883 90.
107. Baron JA Cole BF Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003 348 891 9.
108. Corley DA Kerlikowske K Verma R et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003 124 47 56.
109. Harris RE Chlebowski RT Jackson RD et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003 63 6096 101.
110. Lacey JV Jr. Sherman ME Hartge P et al. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004 108 281 6.
111. Kuenen BC Rosen L Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002 20 1657 67.
112. Icli F Karaoguz H Dincol D et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993 72 587 93.
113. Presta LG Chen H O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 57 4593 9.
114. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004 61 S21 6.
115. Fernando NH Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003 30 39 50.
116. Hurwitz H Fehrenbacher L Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 2335 42.
117. Miller KD Chap LI Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 23 792 9.
118. Johnson DH Fehrenbacher L Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 22 2184 91.
119. Lee CG Heijn M di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000 60 5565 70.
120. Gabrilovich DI Ishida T Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999 5 2963 70.
121. Clauss M Gerlach M Gerlach H et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990 172 1535 45.
122. Calnek DS Grinnell BW. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res 1998 238 294 8.
123. Kroon ME Koolwijk P Vermeer MA et al. Vascular endothelial growth factor enhances the expression of urokinase receptor in human endothelial cells via protein kinase C activation. Thromb Haemost 2001 85 296 302.
124. Kuenen BC Levi M Meijers JC et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002 22 1500 5.
125. Cines DB Pollak ES Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998 91 3527 61.
126. Pearson JD. Endothelial cell function and thrombosis. Baillieres Clin Haematol 1994 7 441 52.
127. Rauch U Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000 10 139 43.
128. Eschbach JW Egrie JC Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987 316 73 8.
129. Rosenzweig MQ Bender CM Lucke JP et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004 27 185 90.
130. Lavey RS Liu PY Greer BE et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol 2004 95 145 51.
131. Dusenbery KE McGuire WA Holt PJ et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994 29 1079 84.
132. Rosenzweig M Bender CM Lucke JP et al. Increased thrombotic events in a clinical trial of erythropoietin (EPO) in metastatic breast cancer. Proc ASCO 2002 21 381.
133. Malyszko J Malyszko JS Borawski J et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995 77 133 43.
134. Ando M Iwata A Ozeki Y et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002 62 1757 63.
135. Taylor JE McLaren M Henderson IS et al. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992 7 235 9.
136. Fuste B Serradell M Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002 88 678 85.
137. Stasko J Drouet L Soria C et al. Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thromb Res 2002 105 161 4.
138. Wang XQ Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999 33 894 9.
139. Zacharski LR Memoli VA Ornstein DL et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993 85 1225 30.
140. von Tempelhoff GF Niemann F Schneider DM et al. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998 90 73 82.
141. Gadducci A Marrai R Baicchi U et al. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gynecol Oncol 1996 61 215 7.